Given FDA Commissioner-nominee Scott Gottlieb's track record as a thought leader on drug pricing policies, some Washington observers have debated whether he might, at least informally, serve as a resource for the Trump administration on these topics going forward. But if approved, he's likely to approach the job in a traditional way and avoid direct involvement in pricing issues.
He signaled as much during his congressional confirmation hearing April 5 in response to a question from Sen. Bernie Sanders,...
